Aligos Therapeutics Inc
ALGS
Get informed when a big investor buys or sells
+ FollowMarket Cap$35.52M
Close$
$-0.44
108.6% downside
Current Fair Value
108.6% downsideOvervalued by 108.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $35.52 Million |
|---|---|
| Enterprise Value | $9.89 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.45 |
| Beta | 2.26 |
| Outstanding Shares | 10,402,967 |
Return
| Return on Equity | -284.13% |
|---|---|
| Return on Assets | -139.91% |
| Return on Invested Capital | -225.00% |
Valuation & Multiples
| P/E Ratio | -0.66 |
|---|---|
| PEG | 0.43 |
| Price to Sales | - |
| Price to Book Ratio | 1.72 |
| Enterprise Value to Revenue | 2.5 |
| Enterprise Value to EBIT | -0.11 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.44 |
| Debt to Equity | 0.14 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 12, 2026
EPS Estimate
$-2.18
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 5, 2026
EPS Estimate
$-1.41
Average shareholder expectationRevenue Estimate
$24.68 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 26.68%▼ 0.43% |
|---|---|
| Total Invested | $20.62M▼ 21.27% |
| Investors Holding | 34▼ 5.00% |
ESG Score
No data
About Aligos Therapeutics Inc
80 employeesAligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the discovery and de...